The hemopoietic events in the embryonic mouse spleen were investigated in fetuses of polycythemic mothers. 12th and 13th day embryonic spleens showed a marked increase in the number of erythroid precursors at an advanced maturation stage, as compared to controls. In addition, an increased erythropoietic activity, measured by 59Fe incorporation into red blood cells of posthypoxic polycythemic mice, was found in the plasma of 12th and 13th day pregnant polycythemic mice, compared with controls, i.e. plasma of nonpregnant nonpolycythemic mice, of nonpregnant polycythemic mice, and of 12th and 13th day pregnant nonpolycythemic mice. Since polycythemic mice are presumed to have low erythropoietin level, the stimulation of erythropoiesis in the embryonic spleens of polycythemic mothers suggests that fetal erythropoiesis is independent of the maternal one. Moreover, the present results indicate that fetuses of polycythemic mothers not only produce their own erythropoietin, but are also able to increase markedly the maternal erythropoietin as a consequence of hypoxemic conditions.

Keywords:
Erythropoiesis, Mouse embryonic spleen, Embryonic erythropoietin
This content is only available via PDF.
© 1981 S. Karger AG, Basel
1981
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.